Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 233 entries
Sorted by: Best Match Show Resources per page
Managing acute promyelocytic leukemia in patients belonging to the Jehovah's Witness congregation.

Hematology reports

Jillella AP, Arellano ML, Heffner LT, Gaddh M, Langston AA, Khoury HJ, Mangoankar A, Kota VK.
PMID: 29071052
Hematol Rep. 2017 Sep 26;9(3):7083. doi: 10.4081/hr.2017.7083. eCollection 2017 Sep 26.

No abstract available.

Cite
Jillella AP, Arellano ML, Heffner LT, et al. Managing acute promyelocytic leukemia in patients belonging to the Jehovah's Witness congregation. Hematol Rep. 2017;9(3):7083doi: 10.4081/hr.2017.7083.
Jillella, A. P., Arellano, M. L., Heffner, L. T., Gaddh, M., Langston, A. A., Khoury, H. J., Mangoankar, A., & Kota, V. K. (2017). Managing acute promyelocytic leukemia in patients belonging to the Jehovah's Witness congregation. Hematology reports, 9(3), 7083. https://doi.org/10.4081/hr.2017.7083
Jillella, Anand P, et al. "Managing acute promyelocytic leukemia in patients belonging to the Jehovah's Witness congregation." Hematology reports vol. 9,3 (2017): 7083. doi: https://doi.org/10.4081/hr.2017.7083
Jillella AP, Arellano ML, Heffner LT, Gaddh M, Langston AA, Khoury HJ, Mangoankar A, Kota VK. Managing acute promyelocytic leukemia in patients belonging to the Jehovah's Witness congregation. Hematol Rep. 2017 Sep 26;9(3):7083. doi: 10.4081/hr.2017.7083. eCollection 2017 Sep 26. PMID: 29071052; PMCID: PMC5641824.
Copy Download .nbib Format: NLM
Evaluating the Expected Costs and Budget Impact of Interventional Therapies for the Treatment of Chronic Venous Disease.

American health & drug benefits

Carlton R, Mallick R, Campbell C, Raju A, O'Donnell T, Eaddy M.
PMID: 26557230
Am Health Drug Benefits. 2015 Oct;8(7):366-74.

BACKGROUND: Chronic venous disease is a common disorder in the United States. The manifestations of chronic venous disease include varicosities and related sequelae that are frequent contributors to the morbidity and high costs associated with the disease. The interventional...

Cite
Carlton R, Mallick R, Campbell C, et al. Evaluating the Expected Costs and Budget Impact of Interventional Therapies for the Treatment of Chronic Venous Disease. Am Health Drug Benefits. 2015;8(7):366-74
Carlton, R., Mallick, R., Campbell, C., Raju, A., O'Donnell, T., & Eaddy, M. (2015). Evaluating the Expected Costs and Budget Impact of Interventional Therapies for the Treatment of Chronic Venous Disease. American health & drug benefits, 8(7), 366-74.
Carlton, Rashad, et al. "Evaluating the Expected Costs and Budget Impact of Interventional Therapies for the Treatment of Chronic Venous Disease." American health & drug benefits vol. 8,7 (2015): 366-74.
Carlton R, Mallick R, Campbell C, Raju A, O'Donnell T, Eaddy M. Evaluating the Expected Costs and Budget Impact of Interventional Therapies for the Treatment of Chronic Venous Disease. Am Health Drug Benefits. 2015 Oct;8(7):366-74. PMID: 26557230; PMCID: PMC4636275.
Copy Download .nbib Format: NLM
Toxicity of organotins towards the marine yeastDebaryomyces hansenii.

Microbial ecology

Laurence OS, Cooney JJ, Gadd GM.
PMID: 24197286
Microb Ecol. 1989 May;17(3):275-85. doi: 10.1007/BF02012840.

Of nine organotin compounds tested towards the marine yeastDebaryomyces hansenii, only triphenyltin chloride (Ph3SnCl) and mono-, di-, and tributyltin chloride induced significant K(+) release from cells which was symptomatic of viability loss. The general order of toxicity of the...

Cite
Laurence OS, Cooney JJ, Gadd GM. Toxicity of organotins towards the marine yeastDebaryomyces hansenii. Microb Ecol. 1989;17(3):275-85doi: 10.1007/BF02012840.
Laurence, O. S., Cooney, J. J., & Gadd, G. M. (1989). Toxicity of organotins towards the marine yeastDebaryomyces hansenii. Microbial ecology, 17(3), 275-85. https://doi.org/10.1007/BF02012840
Laurence, O S, et al. "Toxicity of organotins towards the marine yeastDebaryomyces hansenii." Microbial ecology vol. 17,3 (1989): 275-85. doi: https://doi.org/10.1007/BF02012840
Laurence OS, Cooney JJ, Gadd GM. Toxicity of organotins towards the marine yeastDebaryomyces hansenii. Microb Ecol. 1989 May;17(3):275-85. doi: 10.1007/BF02012840. PMID: 24197286.
Copy Download .nbib Format: NLM
Treatment patterns and outcomes among patients with high-intermediate/high-risk diffuse large B-cell lymphoma in the USA.

Hematology (Amsterdam, Netherlands)

Mytelka DS, Li L, Stafkey-Mailey D, Liepa AM, Hess LM, Farrelly E, Eaddy M.
PMID: 25551431
Hematology. 2015 Sep;20(8):442-448. doi: 10.1179/1607845414Y.0000000228. Epub 2014 Dec 31.

Objective Clinical trials have demonstrated improved outcomes for patients with diffuse large B-cell lymphoma (DLBCL) treated with regimens containing rituximab, but variations in real-world treatment patterns and outcomes have not been studied. The objective of this study was to...

Cite
Mytelka DS, Li L, Stafkey-Mailey D, et al. Treatment patterns and outcomes among patients with high-intermediate/high-risk diffuse large B-cell lymphoma in the USA. Hematology. 2014;20(8):442-448doi: 10.1179/1607845414Y.0000000228.
Mytelka, D. S., Li, L., Stafkey-Mailey, D., Liepa, A. M., Hess, L. M., Farrelly, E., & Eaddy, M. (2015). Treatment patterns and outcomes among patients with high-intermediate/high-risk diffuse large B-cell lymphoma in the USA. Hematology (Amsterdam, Netherlands), 20(8), 442-448. https://doi.org/10.1179/1607845414Y.0000000228
Mytelka, Daniel S, et al. "Treatment patterns and outcomes among patients with high-intermediate/high-risk diffuse large B-cell lymphoma in the USA." Hematology (Amsterdam, Netherlands) vol. 20,8 (2015): 442-448. doi: https://doi.org/10.1179/1607845414Y.0000000228
Mytelka DS, Li L, Stafkey-Mailey D, Liepa AM, Hess LM, Farrelly E, Eaddy M. Treatment patterns and outcomes among patients with high-intermediate/high-risk diffuse large B-cell lymphoma in the USA. Hematology. 2015 Sep;20(8):442-448. doi: 10.1179/1607845414Y.0000000228. Epub 2014 Dec 31. PMID: 25551431.
Copy Download .nbib Format: NLM
Pd-Boron-Catalyzed One Carbon Isomerization of Olefins: Water Assisted Process at Room Temperature.

The Journal of organic chemistry

Ojha DP, Gadde K, Prabhu KR.
PMID: 28402642
J Org Chem. 2017 May 05;82(9):4859-4865. doi: 10.1021/acs.joc.7b00580. Epub 2017 Apr 20.

A palladium-boronate/borane-system -catalyzed isomerization of olefins has been uncovered. An efficient catalytic combination of [Pd(OAc)

Cite
Ojha DP, Gadde K, Prabhu KR. Pd-Boron-Catalyzed One Carbon Isomerization of Olefins: Water Assisted Process at Room Temperature. J Org Chem. 2017;82(9):4859-4865doi: 10.1021/acs.joc.7b00580.
Ojha, D. P., Gadde, K., & Prabhu, K. R. (2017). Pd-Boron-Catalyzed One Carbon Isomerization of Olefins: Water Assisted Process at Room Temperature. The Journal of organic chemistry, 82(9), 4859-4865. https://doi.org/10.1021/acs.joc.7b00580
Ojha, Devi Prasan, et al. "Pd-Boron-Catalyzed One Carbon Isomerization of Olefins: Water Assisted Process at Room Temperature." The Journal of organic chemistry vol. 82,9 (2017): 4859-4865. doi: https://doi.org/10.1021/acs.joc.7b00580
Ojha DP, Gadde K, Prabhu KR. Pd-Boron-Catalyzed One Carbon Isomerization of Olefins: Water Assisted Process at Room Temperature. J Org Chem. 2017 May 05;82(9):4859-4865. doi: 10.1021/acs.joc.7b00580. Epub 2017 Apr 20. PMID: 28402642.
Copy Download .nbib Format: NLM
Anticipated Impact of Generic Imatinib Market Entry on the Costs of Tyrosine Kinase Inhibitors.

American health & drug benefits

Bloudek LM, Makenbaeva D, Eaddy M.
PMID: 26834933
Am Health Drug Benefits. 2015 Dec;8(9):472-80.

BACKGROUND: Imatinib was the first BCR-ABL tyrosine kinase inhibitor (TKI) approved in the United States for the treatment of patients with chronic myelogenous leukemia and is currently the most prescribed TKI. The impending loss of patent exclusivity for imatinib...

Cite
Bloudek LM, Makenbaeva D, Eaddy M. Anticipated Impact of Generic Imatinib Market Entry on the Costs of Tyrosine Kinase Inhibitors. Am Health Drug Benefits. 2015;8(9):472-80
Bloudek, L. M., Makenbaeva, D., & Eaddy, M. (2015). Anticipated Impact of Generic Imatinib Market Entry on the Costs of Tyrosine Kinase Inhibitors. American health & drug benefits, 8(9), 472-80.
Bloudek, Lisa M, et al. "Anticipated Impact of Generic Imatinib Market Entry on the Costs of Tyrosine Kinase Inhibitors." American health & drug benefits vol. 8,9 (2015): 472-80.
Bloudek LM, Makenbaeva D, Eaddy M. Anticipated Impact of Generic Imatinib Market Entry on the Costs of Tyrosine Kinase Inhibitors. Am Health Drug Benefits. 2015 Dec;8(9):472-80. PMID: 26834933; PMCID: PMC4719136.
Copy Download .nbib Format: NLM
Carotid Interventions in Argentina Ñ Our Results and Perspectives.

The Journal of invasive cardiology

Londero HF, Vozzi C, Gadda C, Mendiz O.
PMID: 10762805
J Invasive Cardiol. 1998 Jun;10(5):304-310.

No abstract available.

Cite
Londero HF, Vozzi C, Gadda C, et al. Carotid Interventions in Argentina Ñ Our Results and Perspectives. J Invasive Cardiol. 1998;10(5):304-310
Londero, H. F., Vozzi, C., Gadda, C., & Mendiz, O. (1998). Carotid Interventions in Argentina Ñ Our Results and Perspectives. The Journal of invasive cardiology, 10(5), 304-310.
Londero, et al. "Carotid Interventions in Argentina Ñ Our Results and Perspectives." The Journal of invasive cardiology vol. 10,5 (1998): 304-310.
Londero HF, Vozzi C, Gadda C, Mendiz O. Carotid Interventions in Argentina Ñ Our Results and Perspectives. J Invasive Cardiol. 1998 Jun;10(5):304-310. PMID: 10762805.
Copy Download .nbib Format: NLM
Uptake and intracellular compartmentation of thorium in Saccharomyces cerevisiae.

Environmental pollution (Barking, Essex : 1987)

Gadd GM, White C.
PMID: 15092359
Environ Pollut. 1989;61(3):187-97. doi: 10.1016/0269-7491(89)90240-6.

When Saccharomyces cerevisiae was cultured in the presence of thorium, the element was accumulated by the cells and was visible in electron micrographs as electron dense granules. When thorium was present during exponential growth, these granules were located mainly...

Cite
Gadd GM, White C. Uptake and intracellular compartmentation of thorium in Saccharomyces cerevisiae. Environ Pollut. 1989;61(3):187-97doi: 10.1016/0269-7491(89)90240-6.
Gadd, G. M., & White, C. (1989). Uptake and intracellular compartmentation of thorium in Saccharomyces cerevisiae. Environmental pollution (Barking, Essex : 1987), 61(3), 187-97. https://doi.org/10.1016/0269-7491(89)90240-6
Gadd, G M, and White, C. "Uptake and intracellular compartmentation of thorium in Saccharomyces cerevisiae." Environmental pollution (Barking, Essex : 1987) vol. 61,3 (1989): 187-97. doi: https://doi.org/10.1016/0269-7491(89)90240-6
Gadd GM, White C. Uptake and intracellular compartmentation of thorium in Saccharomyces cerevisiae. Environ Pollut. 1989;61(3):187-97. doi: 10.1016/0269-7491(89)90240-6. PMID: 15092359.
Copy Download .nbib Format: NLM
Home parenteral nutrition in Italy: data from the Italian National Register.

Clinical nutrition (Edinburgh, Scotland)

De Francesco A, Fadda M, Malfi G, De Magistris A, Da Pont MC, Balzola F.
PMID: 16843964
Clin Nutr. 1995 Jun;14:6-9. doi: 10.1016/s0261-5614(95)80273-8.

No abstract available.

Cite
De Francesco A, Fadda M, Malfi G, et al. Home parenteral nutrition in Italy: data from the Italian National Register. Clin Nutr. 1995;14:6-9doi: 10.1016/s0261-5614(95)80273-8.
De Francesco, A., Fadda, M., Malfi, G., De Magistris, A., Da Pont, M. C., & Balzola, F. (1995). Home parenteral nutrition in Italy: data from the Italian National Register. Clinical nutrition (Edinburgh, Scotland), 146-9. https://doi.org/10.1016/s0261-5614(95)80273-8
De Francesco, A, et al. "Home parenteral nutrition in Italy: data from the Italian National Register." Clinical nutrition (Edinburgh, Scotland) vol. 14 (1995): 6-9. doi: https://doi.org/10.1016/s0261-5614(95)80273-8
De Francesco A, Fadda M, Malfi G, De Magistris A, Da Pont MC, Balzola F. Home parenteral nutrition in Italy: data from the Italian National Register. Clin Nutr. 1995 Jun;14:6-9. doi: 10.1016/s0261-5614(95)80273-8. PMID: 16843964.
Copy Download .nbib Format: NLM
Outcome of per protocol best-evidence based routine breast cancer care in a large regional hospital in Belgium: the importance of a prospective database in quality assurance.

Facts, views & vision in ObGyn

Van de Putte G, Vlasselaer J, Teshome B, Gaddah A, Burzykowski T, Schobbens JC, Benijts G, de Jonge ET.
PMID: 25302106
Facts Views Vis Obgyn. 2010;2(2):119-24.

AIM: Criteria for future accreditation of breast cancer centres in Belgium will be mainly based on the case load per surgeon or per centre. We would like to argue that the prospective collection of relevant data and the analysis...

Cite
Van de Putte G, Vlasselaer J, Teshome B, et al. Outcome of per protocol best-evidence based routine breast cancer care in a large regional hospital in Belgium: the importance of a prospective database in quality assurance. Facts Views Vis Obgyn. 2010;2(2):119-24
Van de Putte, G., Vlasselaer, J., Teshome, B., Gaddah, A., Burzykowski, T., Schobbens, J. C., Benijts, G., & de Jonge, E. T. (2010). Outcome of per protocol best-evidence based routine breast cancer care in a large regional hospital in Belgium: the importance of a prospective database in quality assurance. Facts, views & vision in ObGyn, 2(2), 119-24.
Van de Putte, G, et al. "Outcome of per protocol best-evidence based routine breast cancer care in a large regional hospital in Belgium: the importance of a prospective database in quality assurance." Facts, views & vision in ObGyn vol. 2,2 (2010): 119-24.
Van de Putte G, Vlasselaer J, Teshome B, Gaddah A, Burzykowski T, Schobbens JC, Benijts G, de Jonge ET. Outcome of per protocol best-evidence based routine breast cancer care in a large regional hospital in Belgium: the importance of a prospective database in quality assurance. Facts Views Vis Obgyn. 2010;2(2):119-24. PMID: 25302106; PMCID: PMC4188018.
Copy Download .nbib Format: NLM
Retrospective study of risk factors and maternal and fetal outcome in patients with abruptio placentae.

Journal of natural science, biology, and medicine

Mukherjee S, Bawa AK, Sharma S, Nandanwar YS, Gadam M.
PMID: 25097428
J Nat Sci Biol Med. 2014 Jul;5(2):425-8. doi: 10.4103/0976-9668.136217.

INTRODUCTION: Abruptio placentae (AP) which is a major cause of maternal morbidity and perinatal mortality globally is of serious concern in the developing world. We retrospectively analyzed the AP cases and evaluated its impact on fetal and maternal outcomes.MATERIALS...

Cite
Mukherjee S, Bawa AK, Sharma S, et al. Retrospective study of risk factors and maternal and fetal outcome in patients with abruptio placentae. J Nat Sci Biol Med. 2014;5(2):425-8doi: 10.4103/0976-9668.136217.
Mukherjee, S., Bawa, A. K., Sharma, S., Nandanwar, Y. S., & Gadam, M. (2014). Retrospective study of risk factors and maternal and fetal outcome in patients with abruptio placentae. Journal of natural science, biology, and medicine, 5(2), 425-8. https://doi.org/10.4103/0976-9668.136217
Mukherjee, Soma, et al. "Retrospective study of risk factors and maternal and fetal outcome in patients with abruptio placentae." Journal of natural science, biology, and medicine vol. 5,2 (2014): 425-8. doi: https://doi.org/10.4103/0976-9668.136217
Mukherjee S, Bawa AK, Sharma S, Nandanwar YS, Gadam M. Retrospective study of risk factors and maternal and fetal outcome in patients with abruptio placentae. J Nat Sci Biol Med. 2014 Jul;5(2):425-8. doi: 10.4103/0976-9668.136217. PMID: 25097428; PMCID: PMC4121928.
Copy Download .nbib Format: NLM
Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity.

Diabetes, metabolic syndrome and obesity : targets and therapy

Shin JH, Gadde KM.
PMID: 23630428
Diabetes Metab Syndr Obes. 2013 Apr 08;6:131-9. doi: 10.2147/DMSO.S43403. Print 2013.

Qsymia™ (Vivus Inc, Mountain View, CA, USA), a combination of phentermine and delayed-release topiramate, has been available in the US since September 2012 for the treatment of obesity. Phentermine is an anorexigenic agent, which is approved for the short-term...

Cite
Shin JH, Gadde KM. Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity. Diabetes Metab Syndr Obes. 2013;6:131-9doi: 10.2147/DMSO.S43403.
Shin, J. H., & Gadde, K. M. (2013). Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity. Diabetes, metabolic syndrome and obesity : targets and therapy, 6131-9. https://doi.org/10.2147/DMSO.S43403
Shin, Jin Hee, and Gadde, Kishore M. "Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity." Diabetes, metabolic syndrome and obesity : targets and therapy vol. 6 (2013): 131-9. doi: https://doi.org/10.2147/DMSO.S43403
Shin JH, Gadde KM. Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity. Diabetes Metab Syndr Obes. 2013 Apr 08;6:131-9. doi: 10.2147/DMSO.S43403. Print 2013. PMID: 23630428; PMCID: PMC3626409.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 233 entries